To do so, we used data from the Alzheimer’s Disease Neuroimaging Initiatives (ADNI) database, relating to four biomarkers: Aβ (assessed from 18Florbetapir-positron emission tomography (PET)), phosphorylated tau (pTau181, assessed from cerebrospinal fluid), glucose uptake (assessed from 18fluorodeoxyglucose (FDG)-PET), and volumetric measures (assessed from MRI). The gene discussed is MAPT; the disease is Alzheimer disease.